Shots:

• The two studies of AZD7442 will enroll ~6-000 adults for the prevention of COVID-19 in and outside the US- expected to begin in next wk. with additional trials enrolling ~4-000 adults for the treatment of SARS-CoV-2 infections.
• The first study will evaluate the safety and efficacy of AZD7442 to prevent infection for up to 12mos. in ~5-000 participants while the second trial will assess post-exposure prophylaxis and pre-emptive treatment in ~1-100 participants
• AstraZeneca has received ~$486M from US Govt. and plans to supply ~100-000 doses and can acquire other 1M doses. AZD7442 is a combination of 2 LAABs derived from convalescent patients after SARS-CoV-2 infection
  
   ­ Ref: AstraZeneca | Image: The Scientist Magazine